FDA Warns Of Severe Risks Associated With Medtronic Leadless Pacemakers
Medtronic welcomes agency’s recommendations, highlights device’s safety record
Executive Summary
The US Food and Drug Administration has issued a warning to clinicians of the heightened risk for adverse events, including death, from potential cardiac perforation during implantation of Medtronic’s Micra Transcatheter Pacing System (TPS).
You may also be interested in...
HRS 2020: New Trial Data Support Medtronic’s Micra Pacemaker
The Micra CED study showed a lower rate of complications with the Micra leadless pacemaker than transvenous single-chamber pacemakers.
FDA Approves Medtronic’s Micra Leadless Pacemaker With Large Post-Market Trial Condition
The US FDA approved Medtronic’s Micra transcatheter leadless single-chamber pacemaker on April 6, beating out St. Jude’s Nanostim to be the first transcatheter leadless pacemaker to earn FDA approval.
Alarming Rise Of Diabetes in Several US States, Study Shows
A study of diabetes rates across the US over four years reveals significant increases in the disease in many states. Tobias Oerum, diabetes advocate and cofounder of the company that conducted the study, discussed the data and some of the factors contributing to this troubling trend with Medtech Insight.